Followers | 1076 |
Posts | 26372 |
Boards Moderated | 12 |
Alias Born | 01/11/2016 |
Tuesday, January 14, 2020 12:15:32 AM
We are focused on developing our product candidate, ensifentrine, which we believe has the potential to become an important and novel treatment for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other respiratory diseases, including asthma. We own the global commercialization rights to ensifentrine.
Rapidly advance nebulized ensifentrine into Phase 3 for COPD
Nebulized ensifentrine is expected to start Phase 3 clinical trials in 2020 as a maintenance treatment for moderate to severe COPD. Millions of COPD patients urgently need better treatments as they remain symptomatic despite maximum treatment with currently available therapies. In the US alone, total annual medical costs, indirect and direct, relating to COPD are projected to rise to about $50 billion in 2020. We believe ensifentrine will have an important role as an add-on therapy for dual/triple treated patients.
Develop formulations of ensifentrine for handheld inhalers
In addition to nebulized ensifentrine, we have developed dry powder inhaler (DPI) and pressurised metered dose inhaler (pMDI) formulations of ensifentrine for less severe patients. Initial results from Phase 2 trials for the maintenance treatment of COPD are promising. In the US, DPI and pMDI handheld inhalers are the most widely used option for medication in COPD, with an estimated 5.5 million people using them for COPD maintenance therapy. This market was valued at approximately $9 billion in 2018.
Seek strategic relationships
We may seek strategic collaborations with leading biopharmaceutical companies to develop and commercialize ensifentrine. These partnerships could provide significant funding to advance the development of ensifentrine while allowing us to benefit from the development and commercialization expertise of our collaborators.
Develop ensifentrine for cystic fibrosis and severe asthma
We may develop ensifentrine for the treatment of cystic fibrosis and severe asthma. CF is considered an orphan disease by both the US and European regulatory authorities. According to WHO estimates, 300 million people suffer from asthma and it is the most common chronic disease amongst children.
Pursue development of ensifentrine in additional territories
Initially, we are developing ensifentrine for the US and European markets. However, we may also develop ensifentrine for other markets such as China, which has more than 50 million COPD patients and is estimated to grow to 70 million in 2030.
Acquire or in-license product candidates for respiratory diseases
We are leveraging our expertise in respiratory diseases to in-license or acquire additional clinical-stage product candidates. We are seeking assets with the potential to become novel treatments for respiratory diseases with significant unmet medical needs.
Recent VRNA News
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 • GlobeNewswire Inc. • 05/02/2024 06:00:00 AM
- Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/25/2024 06:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/08/2024 09:18:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:40:38 AM
- Andrew Fisher Joins Verona Pharma as General Counsel • GlobeNewswire Inc. • 03/04/2024 07:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 02:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 11:08:57 AM
- Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:11:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:10:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:19:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:07:24 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:02:48 AM
- Michael Austwick Joins Verona Pharma as Non-Executive Director • GlobeNewswire Inc. • 02/01/2024 07:00:00 AM
- Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:02:23 AM
- Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital • GlobeNewswire Inc. • 01/02/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:15:16 PM
- Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award • GlobeNewswire Inc. • 11/17/2023 07:00:00 AM
- Verona Pharma Announces November 2023 Investor Conference Participation • GlobeNewswire Inc. • 11/08/2023 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2023 12:11:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2023 12:09:56 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/03/2023 08:25:55 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM